GEN Exclusives

More »

GEN Poll

More »
May 13, 2013

Genome Sequencing and Patient Autonomy

In a dramatic shift away from the patient’s “right-not-to-know” message pervading clinical genetics since the field’s inception, new guidelines issued by American College of Medical Genetics and Genomics suggest that anyone undergoing genome sequencing for any reason should also be screened for dozens of variants associated with life-threatening but treatable conditions. (Read more about the new guidelines here.) What are your thoughts on this?

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »